|
1) |
Oefelein MG, Smith N, Carter M, et al. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol. 1995;154(6):2128-31. |
2) |
Leibman BD, Dillioglugil O, Wheeler TM, et al. Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level. Cancer. 1995;76(12):2530-4. |
3) |
Lattouf JB, Saad F. Digital rectal exam following prostatectomy:is it still necessary with the use of PSA? Eur Urol. 2003;43(4):333-6. |
4) |
Niwakawa M, Tobisu K, Fujimoto H, et al. Medically and economically appropriate follow-up schedule for prostate cancer patients after radical prostatectomy. Int J Urol. 2002;9(3):134-40. |
5) |
Scattoni V, Montorsi F, Picchio M, et al. Diagnosis of local recurrence after radical prostatectomy. BJU Int. 2004;93(5):680-8. |
6) |
Leventis AK, Shariat SF, Slawin KM. Local recurrence after radical prostatectomy:correlation of US features with prostatic fossa biopsy findings. Radiology. 2001;219(2):432-9. |
7) |
Hricak H, Schoder H, Pucar D, et al. Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Semin Oncol. 2003;30(5):616-34. |
8) |
D'Amico AV, Whittington R, Malkowicz B, et al. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol. 2000;164:759-63. |
9) |
Kane CJ, Amling CL, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003;61(3):607-11. |